Here are four observations:
1. The FDA wanted to create this database to protect patients from faulty devices and to find high-performing innovations.
2. Medical devices only have clinical data before hitting the market, so this database will allow the analysis of real-time, real-world data.
3. Ideally, the collected data would catch device defects and unknown side effects earlier, allowing physicians to readjust treatment plans.
4. The data could also target specific patients who benefit the most from certain devices, which would help manufacturers adjust their marketing.
More articles on devices:
DJO Global 2015 net sales hit $308M; Net loss hits $349.9M: 8 things to know
Mesoblast’s Mesenchymal Precursor Cells receives key patent — 5 takeaways
SpineGuard announces full-year 2015 financial results: 9 facts
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
